Enlivex Ltd. Ordinary Shares

ENLV

Market cap $271M

Additional exchange listing expected to increase token access and contribute to expanded secondary market liquidity for RAIN Nes-Ziona, Israel, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, “Enlivex” or “the Company”) today reported that its primary treasury asset, the RAIN token, has been listed on the Kraken cryptocurrency exchange effective February 9, 2026, further expanding access to the token across an additional digital asset trading platform.

Listing expected to expand market access and secondary liquidity for Enlivex's primary digital treasury asset Nes-Ziona, Israel, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, “Enlivex” or “the Company”) today reported that its primary treasury asset, the RAIN token, has been listed on the WhiteBIT cryptocurrency exchange effective January 21, 2026, expanding access to the token across a major global digital asset trading platform.

Voluntarily Delisting of Ordinary Shares from Trading on the Tel Aviv Stock Exchange to Promote U.S.-Based Trading, Reduce Administrative Costs of Dual Listing

In January, Enlivex Therapeutics Ltd. (NASDAQ: ENLV) reported that its treasury asset, the RAIN token, had been listed on the KuCoin cryptocurrency exchange effective January 6.

Nes-Ziona, Israel, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, “Enlivex” or “the Company”), today announced that it will host a virtual fireside chat on Thursday, December 11, 2025 at 11:00 am ET.

Enlivex Announced today $212,000,000 private placement to initiate world's first prediction markets digital asset treasury strategy, via RAIN token accumulation NESS ZIONA, Israel , Nov. 24, 2025 /PRNewswire/ -- Enlivex Therapeutics Ltd. (NASDAQ: ENLV) today announced the appointment of Mr.

- Upon the closing of the private placement, Enlivex will adopt the world's first RAIN prediction markets token digital asset treasury strategy, via RAIN token accumulation. - RAIN is a fully decentralized predictions and options protocol that redefines predictive market ecosystems and provides a powerful platform for on-chain market creation - built for transparency, automation, and community participation.

Nes-Ziona, Israel, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. ( Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced positive six-month efficacy data from the Phase IIa stage of its randomized, multi-country Phase I/II Allocetra™ trial (ENX-CL-05-001) in patients with moderate to severe knee osteoarthritis (OA). The six-month follow-up has now been completed for all patients. The results re-affirm the three-month data reported previously and substantiate the identification of an age-related primary OA responder population.

Ness-Ziona, Israel, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that it will present a late-breaking poster abstract at the American College of Rheumatology (ACR) Convergence 2025, taking place October 24–29 at McCormick Place Convention Center in Chicago, Illinois.

Nes-Ziona, Israel, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, will participate in a live investor webinar, “Advancing Inflammatory Disease Treatment: Insights & Breakthroughs from Enlivex's Knee Osteoarthritis Program,” hosted by D. Boral Capital on September 30, 2025, at 10:00 AM Eastern Time. The discussion will bring together leading key opinion leaders (KOLs) in musculoskeletal disease, alongside Enlivex's Vice Chairman and D. Boral's Research Director.   The September 30 KOL webinar will explore recent breakthroughs in treatment approaches discussing the positive Phase IIa topline data from Enlivex's Allocetra™ program in moderate-to-severe knee osteoarthritis (KOA) patients. Data demonstrated clinically meaningful and highly statistically significant reduction in pain and improvements in function in idiopathic, age-related knee osteoarthritis patients, a large, underserved population.